Targeted therapies have transformed the outcomes of patients with non-small-cell lung cancer (NSCLC), although only a minor subset of tumours harbours targetable alterations. Now, researchers have developed a PET tracer with a high level of specificity for activating EGFR mutations.
Researchers synthesized a PEGylated anilinoquinazoline derivative (MPG), which was then radiolabelled to enable detection using PET imaging (18F-MPG). Preliminary experiments involving NSCLC-derived cell lines confirmed the in vitro selectivity of this imaging probe for cells harbouring activating EGFR mutations, including a 90% decrease in signal in an EGFR-mutation-positive cell line pretreated with the EGFR inhibitor gefitinib. In vivo studies in mouse models confirmed the safety and metabolic stability of 18F-MPG.
In patients with NSCLC, 18F-MPG was found to selectively accumulate in tumours harbouring EGFR-activating mutations, relative to EGFR-wild-type tumours (F2, 67 = 16.30; P < 0.0001). Applying a standard uptake value (SUVmax) cut-off of 2.23 enabled the discrimination of EGFR-mutant-positive tumours from their EGFR-negative counterparts with a sensitivity of 86.5% and a specificity of 81.8%. A concordance of 84.3% was observed between 18F-MPG using this threshold and amplification refractory mutation system (ARMS)–PCR of tumour biopsy samples for determination of EGFR mutation status.
Among 38 patients who received EGFR-tyrosine-kinase inhibitors on the basis of a tumour SUVmax > 2.23 on 18F-MPG imaging, the objective response rate was 81.6%, versus 46.5% in unselected patients. In one patient, who had stable disease on gefitinib for 20 months, SUVmax was 2.31 after 6 months of treatment. Following disease regression, owing to biopsy-confirmed conversion to an EGFR-wild-type phenotype, SUVmax decreased to 2.01, suggesting sensitivity for acquired resistance. These promising findings warrant prospective validation in patients with NSCLC.
Sun, X. et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci. Transl Med. 10, eaan8840 (2018)
Rights and permissions
About this article
Cite this article
Sidaway, P. PET imaging reveals EGFR mutation status. Nat Rev Clin Oncol 15, 346 (2018). https://doi.org/10.1038/s41571-018-0009-z